Jun 01, 2020
AcelRx Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
May 04, 2020
AcelRx to Host First Quarter 2020 Financial Results Call and Webcast on Monday, May 11th, 2020
Mar 16, 2020
AcelRx Pharmaceuticals to Acquire Tetraphase Pharmaceuticals
Jan 13, 2020
AcelRx Announces Year-End 2019 Metrics and Provides Corporate Updates
Nov 06, 2019
AcelRx Pharmaceuticals Reports Third Quarter 2019 Financial Results
Nov 05, 2019
AcelRx Pharmaceuticals to Present at Credit Suisse 28th Annual Healthcare Conference
Oct 28, 2019
AcelRx to announce third quarter 2019 results and provide an update on the company's business on Wednesday, November 6th, 2019
Oct 16, 2019
Dr. TJ Gan to Present at the 2019 Annual Meeting of the American Society of Anesthesiologists
Aug 15, 2019
AcelRx Pharmaceuticals Selected to Present at the 2019 Military Health System Research Symposium
Aug 05, 2019
AcelRx Pharmaceuticals Reports Second Quarter 2019 Financial Results
Jul 01, 2019
AcelRx added to the Russell 2000® and 3000® indexes
May 08, 2019
AcelRx Pharmaceuticals Reports First Quarter 2019 Financial Results
Apr 25, 2019
AcelRx to announce first quarter 2019 results and provide an update on the company's business on Wednesday, May 8th, 2019
Apr 11, 2019
AcelRx Pharmaceutical's pooled safety results for sufentanil sublingual tablets (DSUVIA) selected for presentation at 44th Annual Regional Anesthesiology & Acute Pain Medicine Meeting
Mar 11, 2019
AcelRx Pharmaceuticals to Present at Oppenheimer & Co. Inc. 29th Annual Healthcare Conference
Mar 07, 2019
AcelRx Pharmaceuticals Announces Commercial Launch of DSUVIA and Reports Fourth Quarter and Full Year 2018 Financial Results
Feb 22, 2019
AcelRx to announce fourth quarter 2018 results and provide a corporate update on Thursday, March 7th, 2019
Jan 31, 2019
AcelRx Pharmaceutical's sufentanil sublingual tablet (DSUVIA) to be highlighted during a presentation at the Boswick Burn and Wound Symposium
Jan 07, 2019
AcelRx Pharmaceuticals announces publication analyzing pooled data on sufentanil sublingual tablets for short-term treatment of moderate-to-severe acute pain
Dec 18, 2018
AcelRx Pharmaceuticals added to the NASDAQ Biotechnology Index (NBI)